Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sajni Josson

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Oncoscience|October 27, 2015
Targeting the tumor-stromal-immune cell axisMurali Gururajan, Sajni Josson, Leland W K Chung
Bio-Protocol|August 30, 2021
<i>In situ</i> Hybridization (ISH) and Quantum Dots (QD) of miRNAsSajni Josson, Murali Gururajan, Leland W K Chung
Bio-Protocol|August 30, 2021
miRNA Characterization from the Extracellular VesiclesSajni Josson, Murali Gururajan, Leland W K Chung
Advances in Experimental Medicine and Biology|December 15, 2015
microRNAs and Prostate CancerSajni Josson, Leland W K Chung, Murali Gururajan
Seminars in Cell & Developmental Biology|December 2, 2009
Tumor-stroma co-evolution in prostate cancer progression and metastasisSajni Josson, Yasuhiro Matsuoka, Leland W K Chung, et al.
The Prostate|August 1, 2008
Radiation modulation of microRNA in prostate cancer cell linesSajni Josson, Shian-Ying Sung, Kaiqin Lao, et al.
Plos One|January 5, 2011
miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymesYong Xu, Fang Fang, Jiayou Zhang, et al.
Molecular Cancer Therapeutics|August 30, 2008
SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiationYong Xu, Fang Fang, Daret K St Clair, et al.
Anti-Cancer Agents in Medicinal Chemistry|July 16, 2013
β2-Microglobulin-mediated signaling as a target for cancer therapyTakeo Nomura, Wen-Chin Huang, Haiyen E Zhau, et al.
Plos One|August 17, 2013
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cellsXiangyan Li, Yi-Ting Chen, Sajni Josson, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Oncoscience|October 27, 2015
Targeting the tumor-stromal-immune cell axisMurali Gururajan, Sajni Josson, Leland W K Chung
Bio-Protocol|August 30, 2021
<i>In situ</i> Hybridization (ISH) and Quantum Dots (QD) of miRNAsSajni Josson, Murali Gururajan, Leland W K Chung
Bio-Protocol|August 30, 2021
miRNA Characterization from the Extracellular VesiclesSajni Josson, Murali Gururajan, Leland W K Chung
Advances in Experimental Medicine and Biology|December 15, 2015
microRNAs and Prostate CancerSajni Josson, Leland W K Chung, Murali Gururajan
Seminars in Cell & Developmental Biology|December 2, 2009
Tumor-stroma co-evolution in prostate cancer progression and metastasisSajni Josson, Yasuhiro Matsuoka, Leland W K Chung, et al.
The Prostate|August 1, 2008
Radiation modulation of microRNA in prostate cancer cell linesSajni Josson, Shian-Ying Sung, Kaiqin Lao, et al.
Plos One|January 5, 2011
miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymesYong Xu, Fang Fang, Jiayou Zhang, et al.
Molecular Cancer Therapeutics|August 30, 2008
SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiationYong Xu, Fang Fang, Daret K St Clair, et al.
Anti-Cancer Agents in Medicinal Chemistry|July 16, 2013
β2-Microglobulin-mediated signaling as a target for cancer therapyTakeo Nomura, Wen-Chin Huang, Haiyen E Zhau, et al.
Plos One|August 17, 2013
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cellsXiangyan Li, Yi-Ting Chen, Sajni Josson, et al.
Pageof 3